Company profile
BioVersys AG
BioVersys AG is a privately owned Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation. With the companys award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means BioVersys addresses the high unmet medical need for new treatments against life threatening resistant bacterial infections and bacteria-exacerbation chronic inflammatory microbiome disorders. Our most advanced R&D programs are in preclinical development for nosocomial infect
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2011
Top 100 Swiss Startup Award 2012
Winner Venture Kick
Innosuisse Certificate
Top 100 Swiss Startup Award 2013
More news about BioVersys AG
